DexCom has launched a proprietary Generative AI (GenAI) platform, which it said makes it the first CGM manufacturer to integrate GenAI into glucose biosensing technology. The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health.
Stelo, an over-the-counter glucose biosensor cleared by the FDA in the United States, is the first Dexcom product to use GenAI-enabled technology to produce weekly insights. The enhancement of Stelo’s Weekly Insights feature started rolling out to users this week. GenAI-powered messaging enhances Stelo’s existing Weekly Insights by offering users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app.
“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualize their health information and make proactive, informed lifestyle decisions.”
Dexcom leveraged Google Cloud’s Vertex AI platform and Gemini models as the foundation to build its proprietary GenAI platform.
“By bringing the power of Google Cloud’s Vertex AI and Gemini to Dexcom’s innovative glucose biosensing technology, users will have more personalized insights to help them make the best decisions for their health,” said Chris Sakalosky, vice president of Strategic Industries for Google Cloud. “Dexcom is empowering people to take control of their metabolic health like never before, and it’s just the beginning of what’s possible as leading organizations bring GenAI to healthcare.”
